ArticleCancers2021

Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro.

Xi-Feng Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.